Celldex Therapeutics Analyst Ratings
Celldex Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/10/2023 | 4.73% | Wells Fargo | → $27 | Upgrades | Underweight → Equal-Weight |
| 11/06/2023 | 210.32% | HC Wainwright & Co. | $73 → $80 | Maintains | Buy |
| 11/03/2023 | 101.71% | Cantor Fitzgerald | $54 → $52 | Maintains | Overweight |
| 10/12/2023 | 109.46% | Cantor Fitzgerald | → $54 | Reiterates | Overweight → Overweight |
| 09/27/2023 | 109.46% | Cantor Fitzgerald | → $54 | Reiterates | Overweight → Overweight |
| 08/22/2023 | -18.54% | Wells Fargo | → $21 | Initiates Coverage On | → Underweight |
| 08/16/2023 | 109.46% | Cantor Fitzgerald | → $54 | Reiterates | Overweight → Overweight |
| 08/10/2023 | 183.17% | HC Wainwright & Co. | → $73 | Reiterates | Buy → Buy |
| 08/09/2023 | 183.17% | HC Wainwright & Co. | → $73 | Reiterates | Buy → Buy |
| 06/12/2023 | 183.17% | HC Wainwright & Co. | → $73 | Reiterates | Buy → Buy |
| 05/31/2023 | 183.17% | HC Wainwright & Co. | → $73 | Reiterates | → Buy |
| 05/05/2023 | 109.46% | Cantor Fitzgerald | $55 → $54 | Maintains | Overweight |
| 05/05/2023 | 183.17% | HC Wainwright & Co. | → $73 | Reiterates | → Buy |
| 03/22/2023 | 183.17% | HC Wainwright & Co. | → $73 | Reiterates | → Buy |
| 03/01/2023 | 183.17% | HC Wainwright & Co. | → $73 | Reiterates | → Buy |
| 02/27/2023 | 183.17% | HC Wainwright & Co. | → $73 | Reiterates | → Buy |
| 11/11/2022 | 144.38% | Guggenheim | $68 → $63 | Maintains | Buy |
| 08/09/2022 | 148.25% | SVB Leerink | $68 → $64 | Maintains | Outperform |
| 07/01/2022 | 183.17% | HC Wainwright & Co. | $60 → $73 | Maintains | Buy |
| 09/17/2021 | 156.01% | Jefferies | → $66 | Initiates Coverage On | → Buy |
| 09/13/2021 | 132.74% | HC Wainwright & Co. | $54 → $60 | Maintains | Buy |
| 09/10/2021 | 163.77% | SVB Leerink | → $68 | Initiates Coverage On | → Outperform |
| 08/06/2021 | 109.46% | HC Wainwright & Co. | $50 → $54 | Maintains | Buy |
| 07/22/2021 | 156.01% | Guggenheim | → $66 | Initiates Coverage On | → Buy |
| 07/12/2021 | 93.95% | HC Wainwright & Co. | $36 → $50 | Maintains | Buy |
| 02/23/2021 | 39.64% | HC Wainwright & Co. | $25 → $36 | Maintains | Buy |
| 10/19/2020 | -3.03% | HC Wainwright & Co. | $16 → $25 | Maintains | Buy |
| 03/27/2020 | -37.94% | HC Wainwright & Co. | $19 → $16 | Reiterates | → Buy |
| 02/21/2020 | -68.97% | Cantor Fitzgerald | → $8 | Initiates Coverage On | → Overweight |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 11/10/2023 | 4.73% | 富國銀行 | → 27 美元 | 升級 | 體重不足 → 重量相等 |
| 11/06/2023 | 210.32% | HC Wainwright & Co. | 73 美元 → 80 美元 | 維護 | 買 |
| 11/03/2023 | 101.71% | 坎託·菲茨傑拉德 | 54 美元 → 52 美元 | 維護 | 超重 |
| 2023 年 12 月 10 日 | 109.46% | 坎託·菲茨傑拉德 | → 54 美元 | 重申 | 超重 → 超重 |
| 09/27/2023 | 109.46% | 坎託·菲茨傑拉德 | → 54 美元 | 重申 | 超重 → 超重 |
| 08/22/2023 | -18.54% | 富國銀行 | → 21 美元 | 啓動覆蓋範圍開啓 | → 體重不足 |
| 08/16/2023 | 109.46% | 坎託·菲茨傑拉德 | → 54 美元 | 重申 | 超重 → 超重 |
| 08/10/2023 | 183.17% | HC Wainwright & Co. | → 73 美元 | 重申 | 購買 → 購買 |
| 08/09/2023 | 183.17% | HC Wainwright & Co. | → 73 美元 | 重申 | 購買 → 購買 |
| 06/12/2023 | 183.17% | HC Wainwright & Co. | → 73 美元 | 重申 | 購買 → 購買 |
| 05/31/2023 | 183.17% | HC Wainwright & Co. | → 73 美元 | 重申 | → 購買 |
| 05/05/2023 | 109.46% | 坎託·菲茨傑拉德 | 55 美元 → 54 美元 | 維護 | 超重 |
| 05/05/2023 | 183.17% | HC Wainwright & Co. | → 73 美元 | 重申 | → 購買 |
| 03/22/2023 | 183.17% | HC Wainwright & Co. | → 73 美元 | 重申 | → 購買 |
| 03/01/2023 | 183.17% | HC Wainwright & Co. | → 73 美元 | 重申 | → 購買 |
| 02/27/2023 | 183.17% | HC Wainwright & Co. | → 73 美元 | 重申 | → 購買 |
| 11/11/2022 | 144.38% | 古根海姆 | 68 美元 → 63 美元 | 維護 | 買 |
| 08/09/2022 | 148.25% | SVB Leerink | 68 美元 → 64 美元 | 維護 | 跑贏大盤 |
| 2022 年 1 月 7 日 | 183.17% | HC Wainwright & Co. | 60 美元 → 73 美元 | 維護 | 買 |
| 09/17/2021 | 156.01% | 傑富瑞集團 | → 66 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 09/13/2021 | 132.74% | HC Wainwright & Co. | 54 美元 → 60 美元 | 維護 | 買 |
| 2021 年 10 月 9 日 | 163.77% | SVB Leerink | → 68 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
| 2021 年 6 月 8 日 | 109.46% | HC Wainwright & Co. | 50 美元 → 54 美元 | 維護 | 買 |
| 07/22/2021 | 156.01% | 古根海姆 | → 66 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 07/12/2021 | 93.95% | HC Wainwright & Co. | 36 美元 → 50 美元 | 維護 | 買 |
| 2021 年 2 月 23 日 | 39.64% | HC Wainwright & Co. | 25 美元 → 36 美元 | 維護 | 買 |
| 2020 年 10 月 19 日 | -3.03% | HC Wainwright & Co. | 16 美元 → 25 美元 | 維護 | 買 |
| 03/27/2020 | -37.94% | HC Wainwright & Co. | 19 美元 → 16 美元 | 重申 | → 購買 |
| 02/21/2020 | -68.97% | 坎託·菲茨傑拉德 | → 8 美元 | 啓動覆蓋範圍開啓 | → 超重 |
What is the target price for Celldex Therapeutics (CLDX)?
Celldex Therapeutics（CLDX）的目標價格是多少？
The latest price target for Celldex Therapeutics (NASDAQ: CLDX) was reported by Wells Fargo on November 10, 2023. The analyst firm set a price target for $27.00 expecting CLDX to rise to within 12 months (a possible 4.73% upside). 17 analyst firms have reported ratings in the last year.
富國銀行於2023年11月10日公佈了Celldex Therapeutics（納斯達克股票代碼：CLDX）的最新目標股價。該分析公司將目標股價定爲27.00美元，預計CLDX將在12個月內升至12個月內（可能上漲4.73％）。去年有17家分析公司公佈了評級。
What is the most recent analyst rating for Celldex Therapeutics (CLDX)?
分析師對Celldex Therapeutics（CLDX）的最新評級是多少？
The latest analyst rating for Celldex Therapeutics (NASDAQ: CLDX) was provided by Wells Fargo, and Celldex Therapeutics upgraded their equal-weight rating.
富國銀行對Celldex Therapeutics（納斯達克股票代碼：CLDX）的最新分析師評級由富國銀行提供，Celldex Therapeutics上調了同等權重評級。
When is the next analyst rating going to be posted or updated for Celldex Therapeutics (CLDX)?
Celldex Therapeutics（CLDX）的下一個分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Celldex Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Celldex Therapeutics was filed on November 10, 2023 so you should expect the next rating to be made available sometime around November 10, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與Celldex Therapeutics的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級，因此每家公司每年應該獲得4次評級。Celldex Therapeutics的最新評級是在2023年11月10日公佈的，因此您應該預計下一個評級將在2024年11月10日左右公佈。
Is the Analyst Rating Celldex Therapeutics (CLDX) correct?
分析師對 Celldex Therapeutics (CLDX) 的評級正確嗎？
While ratings are subjective and will change, the latest Celldex Therapeutics (CLDX) rating was a upgraded with a price target of $0.00 to $27.00. The current price Celldex Therapeutics (CLDX) is trading at is $25.78, which is within the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但最新的Celldex Therapeutics（CLDX）評級已上調，目標股價爲0.00美元，至27.00美元。Celldex Therapeutics（CLDX）目前的交易價格爲25.78美元，在分析師的預測區間內。
譯文內容由第三人軟體翻譯。